Biomembrane-derived nanoplexes for SiRNAs-pioneer innovation in delivery to lung adenocarcinoma
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (85)
Show source-provided references
1. Zhang L, Wang Y, Xia T, Yu Q, Zhao R (2018) Strategies in the delivery of siRNA therapeutics for cancer treatment. J Biomed Mater Res A 107(2):432–444
2. Parodi A, Quattrocchi N, van de Ven AL, Chiappini C, Evangelopoulos M, Martinez JO et al (2017) Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery. Biomaterials. 147:155–16810.1016/j.biomaterials.2017.09.020 ↗
3. Marín-Menéndez A, Montis C, Díaz-Calvo T, Carta D, Hatzixanthis K, Morris CJ, McArthur M, Berti D (2017) Antimicrobial nanoplexes meet model bacterial membranes: the key role of Cardiolipin. Sci Rep 7(1):4124210.1038/srep41242 ↗
4. Kanasty R, Dorkin JR, Vegas A, Anderson D (2013) Delivery materials for siRNA therapeutics. Nat Mater 12(11):967–97710.1038/nmat3765 ↗
5. Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U et al (2013) Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 31(7):638–64610.1038/nbt.2612 ↗
6. Aryal S, Hu CM, Zhang L (2011) Polymer–cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano 5(1):138–143
7. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK (2011) RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11(1):59–6710.1038/nrc2966 ↗
8. Zhang P, Liu G, Chen X (2017) Nanobiotechnology: cell membrane-based delivery systems. Nano Today 13:7–910.1016/j.nantod.2016.10.008 ↗
9. Tran S, DeGiovanni PJ, Piel B, Rai P (2017) Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med 6(1):4410.1186/s40169-017-0175-0 ↗
10. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6(3):659–66810.1021/mp900015y ↗
11. Bobbin ML, Rossi JJ (2016) RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol 56:103–12210.1146/annurev-pharmtox-010715-103633 ↗
12. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411(6836):494–49810.1038/35078107 ↗
13. Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y (2014) Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Eng 53(46):12320–1236410.1002/anie.201403036 ↗
14. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST (2017) Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev 108:25–3810.1016/j.addr.2016.04.025 ↗
15. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–2510.1016/j.addr.2013.11.009 ↗
16. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R et al (2012) Treating metastatic cancer with nanotechnology. Nat Rev Cancer 12(1):39–5010.1038/nrc3180 ↗
17. Allen TM, Cullis PR (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65(1):36–4810.1016/j.addr.2012.09.037 ↗
18. Whitehead KA, Dorkin JR, Vegas AJ, Chang PH, Veiseh O, Matthews J et al (2014) Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun 5:427710.1038/ncomms5277 ↗
19. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751–76010.1038/nnano.2007.387 ↗
20. Burnett JC, Rossi JJ (2012) RNA-based therapeutics: current progress and future prospects. Chem Biol 19(1):60–7110.1016/j.chembiol.2011.12.008 ↗
21. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ et al (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3(4):406–41710.1158/2159-8290.CD-12-0429 ↗
22. Woodcock J, Griffin JP, Behrman RE (2011) Development of novel combination therapies. N Engl J Med 364(11):985–98710.1056/NEJMp1101548 ↗
23. Chen Y, Zhu X, Zhang X, Liu B, Huang L (2010) Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 18(9):1650–165610.1038/mt.2010.136 ↗
24. Conde J, Doria G, Baptista P (2012) Noble metal nanoparticles applications in cancer. J Drug Deliv 2012:75107510.1155/2012/751075 ↗
25. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S (2009) Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 4:99–105
26. Anthiya S, Öztürk SC, Yanik H, Tavukcuoglu E, Şahin A, Datta D, Charisse K, Álvarez DM, Loza MI, Calvo A, Sulheim E (2023) Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors. J Control Release 357:67–8310.1016/j.jconrel.2023.03.016 ↗
27. Laskar P, Jaggi M, Chauhan SC, Yallapu MM (2023) Biomolecule-functionalized nanoformulations for prostate cancer theranostics. J Adv Res 51:197–21710.1016/j.jare.2022.11.001 ↗
28. Zhang M, Lu H, Xie L, Liu X, Cun D, Yang M (2023) Inhaled RNA drugs to treat lung diseases: disease-related cells and nano–bio interactions. Adv Drug Deliv Rev 203: 115144.10.1016/j.addr.2023.115144 ↗
29. Garg SS, Dubey R, Sharma S, Vyas A, Gupta J (2023) Biological macromolecules-based nanoformulation in improving wound healing and bacterial biofilm-associated infection: a review. Int J Biol Macromol 247: 12563610.1016/j.ijbiomac.2023.125636 ↗
30. Ahmad A, Rashid S, Chaudhary AA, Alawam AS, Alghonaim MI, Raza SS, Khan R (2023) Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors. Semin Cancer Biol 89:38–6010.1016/j.semcancer.2023.01.002 ↗
31. Sazdova I, Keremidarska-Markova M, Dimitrova D, Mitrokhin V, Kamkin A, Hadzi-Petrushev N, Bogdanov J, Schubert R, Gagov H, Avtanski D, Mladenov M (2023) Anticarcinogenic potency of EF24: an overview of its pharmacokinetics, efficacy, mechanism of action, and nanoformulation for drug delivery. cancers. 15(22):547810.3390/cancers15225478 ↗
32. Wittrup A, Lieberman J (2015) Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet 16(9):543–55210.1038/nrg3978 ↗
33. Gao J, Chen K, Luong R (2014) Liposomal nanocarriers for siRNA delivery. J Biotechnol Biomater 4(1):166
34. Zhang Y, Huang L, Li Z (2017) Biomembrane-coated nanoparticles for drug delivery systems. Curr Med Chem 24(14):1379–1395
35. Sun Q, Zhou Z, Qiu N, Shen Y (2017) Rational design of cancer nanomedicine: nanoproperty integration and synchronization. Adv Mater 29(14):160662810.1002/adma.201606628 ↗
36. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10(9):1243–126010.1097/JTO.0000000000000630 ↗
37. Li Y, Wang J, Wientjes MG, Au JL (2012) Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev 64(1):29–3910.1016/j.addr.2011.04.006 ↗
38. Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L (2011) Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA 108(27):10980–1098510.1073/pnas.1106634108 ↗
39. Setten RL, Rossi JJ, Han SP (2019) The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov 18(6):421–44610.1038/s41573-019-0017-4 ↗
40. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A (2012) Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 338(6109):903–91010.1126/science.1226338 ↗
41. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8(2):129–13810.1038/nrd2742 ↗
42. Ozpolat B, Sood AK, Lopez-Berestein G (2014) Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 66:110–11610.1016/j.addr.2013.12.008 ↗
43. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–3410.3322/caac.21551 ↗
44. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G et al (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32(19):e14910.1093/nar/gnh140 ↗
45. Jensen SA, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM et al (2013) Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med 5(209):209ra15210.1126/scitranslmed.3006839 ↗
46. Li J, Chen YC, Tseng YC, Mozumdar S, Huang L (2010) Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release 142(3):416–42110.1016/j.jconrel.2009.11.008 ↗
47. Kim HJ, Kim A, Miyata K, Kataoka K (2016) Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Deliv Rev 104:61–7710.1016/j.addr.2016.06.011 ↗
48. Lee H, Lytton-Jean AK, Chen Y, Love KT, Park AI, Karagiannis ED et al (2012) Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol 7(6):389–39310.1038/nnano.2012.73 ↗
49. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK et al (2007) Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 104(14):5715–572110.1073/pnas.0701458104 ↗
50. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA et al (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 464(7291):1067–107010.1038/nature08956 ↗
51. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N et al (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26(5):561–56910.1038/nbt1402 ↗
52. de Castro KC, Coco JC, Dos Santos ÉM, Ataide JA, Martinez RM, do Nascimento MH, Prata J, da Fonte PR, Severino P, Mazzola PG, Baby AR (2023) Pluronic® triblock copolymer-based nanoformulations for cancer therapy: a 10-year overview. J Control Release 353:802–82210.1016/j.jconrel.2022.12.017 ↗
53. Chang YT, Huang TH, Alalaiwe A, Hwang E, Fang JY (2023) Small interfering RNA-based nanotherapeutics for treating skin-related diseases. Expert Opin Drug Deliv 27:1–6
54. Kaps L, Limeres MJ, Schneider P, Svensson M, Zeyn Y, Fraude S, Cacicedo ML, Galle PR, Gehring S, Bros M (2023) Liver cell type-specific targeting by nanoformulations for therapeutic applications. Int J Mol Sci 24(14):1186910.3390/ijms241411869 ↗
55. Swarts DC, Makarova K, Wang Y, Nakanishi K, Ketting RF, Koonin EV et al (2014) The evolutionary journey of Argonaute proteins. Nat Struct Mol Biol 21(9):743–75310.1038/nsmb.2879 ↗
56. Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG (2012) Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther 20(3):513–52410.1038/mt.2011.294 ↗
57. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA (2004) In vivo activity of nuclease-resistant siRNAs. RNA. 10(5):766–77110.1261/rna.5239604 ↗
58. Conde J, Ambrosone A, Sanz V, Hernandez Y, Marchesano V, Tian F et al (2012) Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing. ACS Nano 6(9):8316–832410.1021/nn3030223 ↗
59. Daka A, Peer D (2012) RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev 64(13):1508–152110.1016/j.addr.2012.08.014 ↗
60. Zuckerman JE, Gritli I, Tolcher A, Heidel JD, Lim D, Morgan R et al (2014) Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci USA 111(31):11449–1145410.1073/pnas.1411393111 ↗
61. Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY et al (2017) Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA). Mol Cancer Ther 16(6):1114–112310.1158/1535-7163.MCT-16-0541 ↗
62. Williford JM, Wu J, Ren Y, Archang MM, Leong KW, Mao HQ (2014) Recent advances in nanoparticle-mediated siRNA delivery. Annu Rev Biomed Eng 16:347–37010.1146/annurev-bioeng-071813-105119 ↗
63. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG (2010) Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 267(1):9–2110.1111/j.1365-2796.2009.02189.x ↗
64. Jain D, Prajapati SK, Jain A, Singhal R (2023) Nano-formulated siRNA-based therapeutic approaches for cancer therapy. Nano Trends 1:10000610.1016/j.nwnano.2023.100006 ↗
65. Lima ES, Dos Santos D, Souza AL, Macedo ME, Bandeira ME, Junior SS, Fiuza BS, Rocha VP, dos Santos Fonseca LM, Nunes DD, Hodel KV (2023) RNA combined with nanoformulation to advance therapeutic technologies. Pharmaceuticals. 16(12):163410.3390/ph16121634 ↗
66. Kandasamy G, Maity D (2023) Current advancements in self-assembling nanocarriers-based siRNA delivery for cancer therapy. Colloids Surf B: Biointerfaces 221:11300210.1016/j.colsurfb.2022.113002 ↗
67. Paul A, Biswas A, Chatterjee S, Raj A, Raychaudhuri R, Mutalik S, Alex AT (2023) Development, optimization, and evaluation of nano-platforms for delivery of siRNA and BPTES in c-Myc induced breast cancer. J Pharm Innov 31:1–25
68. Dong Y, Siegwart DJ, Anderson DG (2019) Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev 144:133–14710.1016/j.addr.2019.05.004 ↗
69. Burnett JC, Rossi JJ, Tiemann K (2011) Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 6(9):1130–114610.1002/biot.201100054 ↗
70. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 432(7014):173–17810.1038/nature03121 ↗
71. Molitoris BA, Dagher PC, Sandoval RM, Campos SB, Ashush H, Fridman E et al (2009) siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 20(8):1754–176410.1681/ASN.2008111204 ↗
72. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR et al (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 441(7092):537–54110.1038/nature04791 ↗
73. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A (2005) RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12(5):461–46610.1038/sj.gt.3302425 ↗
74. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23(8):1002–100710.1038/nbt1122 ↗
75. Thakur A, Vaishampayan U (2018) Nanoparticles in the treatment of cancers. Biochem Pharmacol 154:110–123
76. Lee JB, Hong J, Bonner DK, Poon Z, Hammond PT (2012) Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater 11(4):316–32210.1038/nmat3253 ↗
77. Kaczmarek JC, Patel AK, Kauffman KJ, Fenton OS, Webber MJ, Heartlein MW et al (2019) Efficient mRNA delivery with graphene oxide-polyethylenimine for generation of footprint-free human induced pluripotent stem cells. J Control Release 306:172–181
78. Guo P, You JO, Yang J, Jia D, Moses MA, Auguste DT (2014) Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm 11(3):755–76510.1021/mp4004699 ↗
79. Huang S, Shao K, Liu Y, Kuang Y, Li J, An S et al (2013) Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano 7(3):2860–287110.1021/nn400548g ↗
80. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MØ et al (2006) RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 14(4):476–48410.1016/j.ymthe.2006.04.010 ↗
81. Zhu L, Kate P, Torchilin VP (2012) Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 6(4):3491–349810.1021/nn300524f ↗
82. Jeong JH, Park TG, Kim SH (2014) Self-assembled and nanostructured siRNA delivery carriers. Nano Today 9(4):438–458
83. Xiong F, Mi Z, Gu N (2011) Magnetic nanoparticles: recent developments in drug delivery system. Drug Dev Ind Pharm 37(7):613–623
84. Ramasamy T, Ruttala HB, Sundaramoorthy P, Poudel BK, Youn YS, Ku SK et al (2015) Engineering of a lipid-polymer nanoarchitectural platform for highly effective combination therapy of doxorubicin and irinotecan. Chem Commun 51(27):5758–576110.1039/C5CC00482A ↗
85. Wang Y, Gao S, Ye WH, Yoon HS, Yang YY (2006) Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 5(10):791–79610.1038/nmat1737 ↗